U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H19ClN4O4
Molecular Weight 426.853
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LENVATINIB

SMILES

COC1=CC2=C(C=C1C(N)=O)C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=N2

InChI

InChIKey=WOSKHXYHFSIKNG-UHFFFAOYSA-N
InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)

HIDE SMILES / InChI
Molecular Formula C21H19ClN4O4
Molecular Weight 426.853
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
123738
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:48:19 UTC 2023
Edited
by admin
on Fri Dec 15 15:48:19 UTC 2023
Record UNII
EE083865G2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LENVATINIB
DASH   INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
4-(3-CHLORO-4-((CYCLOPROPYLAMINOCARBONYL)AMINO)PHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE
Systematic Name English
6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-
Systematic Name English
lenvatinib [INN]
Common Name English
ER-203492-00
Code English
E-7080
Code English
LENVATINIB [MI]
Common Name English
LENVATINIB [USAN]
Common Name English
6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)- 7-METHOXY-
Systematic Name English
Lenvatinib [WHO-DD]
Common Name English
E7080
Code English
4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE
Systematic Name English
N-(4-((6-CARBAMOYL-7-METHOXYQUINOLIN-4-YL)OXY)-2-CHLOROPHENYL)-N'-CYCLOPROPYLUREA
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
FDA ORPHAN DRUG 423614
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
NCI_THESAURUS C93259
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
WHO-ATC L01XE29
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
FDA ORPHAN DRUG 378412
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
FDA ORPHAN DRUG 423714
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
NDF-RT N0000175605
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
EU-Orphan Drug EU/3/15/1460
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
Code System Code Type Description
CHEBI
85994
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
USAN
XX-26
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
FDA UNII
EE083865G2
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
CAS
417716-92-8
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
INN
9361
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
ChEMBL
CHEMBL1289601
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
LACTMED
Lenvatinib
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
MERCK INDEX
m6764
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
LENVATINIB
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
DRUG BANK
DB09078
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
IUPHAR
7426
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
RXCUI
1603296
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY RxNorm
DRUG CENTRAL
4942
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
EVMPD
SUB64419
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
NCI_THESAURUS
C95124
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
CHEBI
85995
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
NDF-RT
N0000020000
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY Receptor Tyrosine Kinase Inhibitors [MoA]
EPA CompTox
DTXSID50194605
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
PUBCHEM
9823820
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
DAILYMED
EE083865G2
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
SMS_ID
100000134793
Created by admin on Fri Dec 15 15:48:19 UTC 2023 , Edited by admin on Fri Dec 15 15:48:19 UTC 2023
PRIMARY
Related Record Type Details
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Predicted no effect with other CYP2C8 substrates at clinical dose of Lenvatinib
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2C8
METABOLIC ENZYME -> INHIBITOR
INHIBITOR
PLASMA
Structure of LENVATINIB MESYLATE
SALT/SOLVATE -> PARENT
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
TARGET -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
Time-dependent inhibition. significant effect with other drugs which are substrate of CYP3A4 at clinical dose of Lenvatinib
MAJOR
PLASMA
Related Record Type Details
Structure of ME-92
METABOLITE INACTIVE -> PARENT
MINOR
PLASMA
Structure of 4-(4-((AMINOCARBONYL)AMINO)-3-CHLOROPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE
METABOLITE LESS ACTIVE -> PARENT
MINOR
PLASMA
Structure of 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-1,2-DIHYDRO-7-METHOXY-2-OXO-6-QUINOLINECARBOXAMIDE
METABOLITE LESS ACTIVE -> PARENT
MINOR
URINE
Structure of ME-107
METABOLITE LESS ACTIVE -> PARENT
MINOR
PLASMA
Structure of 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-1,2-DIHYDRO-7-METHOXY-2-OXO-6-QUINOLINECARBOXAMIDE
METABOLITE LESS ACTIVE -> PARENT
MINOR
FECAL
Structure of 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-HYDROXY-6-QUINOLINECARBOXAMIDE
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA
Structure of 1,4-DIHYDRO-7-METHOXY-4-OXO-6-QUINOLINECARBOXAMIDE
METABOLITE INACTIVE -> PARENT
MINOR
PLASMA
Structure of 4-(4-AMINO-3-CHLOROPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE
METABOLITE LESS ACTIVE -> PARENT
MINOR
PLASMA
Related Record Type Details
Structure of LENVATINIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966